Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00297258
Recruitment Status : Completed
First Posted : February 28, 2006
Results First Posted : January 6, 2010
Last Update Posted : February 3, 2016
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the activity and tolerability of pazopanib in subjects with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists and to characterize the pharmacokinetics of pazopanib in this subject population.

Condition or disease Intervention/treatment Phase
Sarcoma, Soft Tissue Drug: pazopanib Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 148 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma
Study Start Date : November 2005
Actual Primary Completion Date : February 2014
Actual Study Completion Date : February 2014

Intervention Details:
  • Drug: pazopanib
    oral tablet
    Other Name: GW786034

Primary Outcome Measures :
  1. Progression Free Survival at Week 12 [ Time Frame: Week 12 ]
    Progression free survival at week 12 is the number of participants who had a complete response (CR, all detectable tumor had disappeared) or a partial response (PR, a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum) or stable disease (SD, no change) 12 weeks from start of therapy, per response evaluation criteria in solid tumors (RECIST v1.0). Clinical progression is progression of disease without documented radiological evidence. Progressive disease (PD), a >=20% increase in target lesions.

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: Start of therapy until death (up to approximately 5 years) ]
    Overall survival is defined as the time from start of therapy until death. Participants who were still alive at the time of analysis were censored.

  2. Progression Free Survival [ Time Frame: Start of therapy until progression (up to approximately 5 years) ]
    Progression free survival is defined as the interval between the start of treatment and the earliest date of disease progression or death due to any cause. Assessments of progression were made by the investigator.

  3. Overall Response [ Time Frame: Baseline until either response or progression (up to approximately 5 years) ]
    Overall response is the number of participants who had a best outcome of a complete response (CR, all detectable tumor had disappeared) or a partial response (PR, a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum) per response evaluation criteria in solid tumors (RECIST v1.0) at some point during the study. Progressive disease (PD), a >=20% increase in target lesions. Clinical progression is progression of disease without documented radiological evidence.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological evidence of high or intermediate grade malignant soft tissue sarcoma, or cytological evidence in case of presence of multiple metastases. List of eligible and ineligible tumours are included in the protocol.
  • Formalin fixed paraffin embedded tumour blocks and representative H/E (haematoxylin/eosin) slides must be available for histological central review. Histological central review is not required before treatment start but is mandatory within 3 months of registration. Local histopathological diagnosis will be accepted for entry into the study.
  • Presence of measurable disease (according to RECIST criteria).
  • Relapsed or refractory disease incurable by surgery or radiotherapy.
  • Evidence of objective progression within the last 6 months (RECIST) documented by measurements of disease,
  • Patients must either not be eligible for chemotherapy (for instance because of age, or because of a biological condition, or because of patient-refusal) or must have received no more than one combination or two single agents chemotherapy regimen for advanced disease; (neo) adjuvant therapy is not counted towards this requirement.
  • At least 18 years of age
  • WHO performance status 0 or 1
  • Adequate bone marrow function
  • Adequate hepatic function
  • Adequate renal function
  • PT / PTT less than 1.2 x UNL.
  • LVEF above the lower limit of normal for the institution, based on ECHO or MUGA
  • Able to swallow and retain oral medication
  • Women should not be of childbearing potential and agree to use contraceptive methods (Oral contraceptives are not allowed).
  • Absence of any serious and/or unstable pre-existing medical, psychiatric or other condition (including lab abnormality) that could interfere with patient safety or obtaining informed consent.
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before registration in the trial.
  • Written informed consent is given according to ICH/GCP, and national/local regulations before patient registration/randomization.

Exclusion Criteria:

  • history of leptomeningeal or brain metastases
  • history of malignancies other than sarcoma (except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or the patient has been free of any other malignancies for greater than 3 years).
  • Class II, III or IV heart failure (NYHA classification). A patient who has a history of class II heart failure and is asymptomatic on treatment may be considered eligible.
  • Arterial or venous thrombosis, myocardial infarction, unstable angina, cardiac angioplasty or stenting within the last 3 months
  • Uncontrolled or poorly controlled hypertension. Initiation or adjustment of BP medications is permitted prior to study entry, provided that patient has 3 consecutive BP readings less than 150 / 90 mm Hg each separated by a minimum of 24 hrs. These readings need to be collected prior to registration in the study.
  • Women of childbearing potential, who are pregnant (negative serum pregnancy test at entry) or lactating.
  • Therapeutic dose warfarin. Low molecular weight heparin and prophylactic low dose warfarin are permitted. PT/INR and PPT must meet the above inclusion criteria.
  • Concurrent therapy with any specifically prohibited medication or requirement for using any of these medications during treatment with pazopanib
  • Major surgery, hormonal therapy (other than replacement), chemotherapy or radiotherapy, immunotherapy or other investigational agent within the last 28 days and/or not recovered from prior therapy within the last 28 days. Use of erythropoietin is considered supportive care and is permitted. The patient should have recovered from prior surgery and have no open wounds.
  • History of malabsorption syndrome, disease significantly affecting gastrointestinal function or major resection of the stomach or small bowel that could affect absorption, distribution, metabolism or excretion of study drugs. No unresolved bowel obstruction or diarrhea.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00297258

GSK Investigational Site
Bruxelles, Belgium, 1000
GSK Investigational Site
Leuven, Belgium, 3000
GSK Investigational Site
Lyon cedex 03, France, 69437
GSK Investigational Site
Marseille, France, 13385
GSK Investigational Site
Paris Cedex 05, France, 75248
GSK Investigational Site
Villejuif, France, 94805
GSK Investigational Site
Budapest, Hungary, 01135
GSK Investigational Site
Groningen, Netherlands, 9713 GZ
GSK Investigational Site
Leiden, Netherlands, 2300 RC
GSK Investigational Site
Rotterdam, Netherlands, 3075 EA
United Kingdom
GSK Investigational Site
Manchester, Lancashire, United Kingdom, M20 4BX
GSK Investigational Site
Glasgow, United Kingdom, G11 6NT
GSK Investigational Site
Leeds, United Kingdom, LS9 7TF
GSK Investigational Site
London, United Kingdom, SW3 6JJ
GSK Investigational Site
Newcastle upon Tyne, United Kingdom, NE7 7DN
GSK Investigational Site
Sheffield, United Kingdom, S10 2SJ
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: GlaxoSmithKline Identifier: NCT00297258     History of Changes
Obsolete Identifiers: NCT00293449
Other Study ID Numbers: VEG20002
First Posted: February 28, 2006    Key Record Dates
Results First Posted: January 6, 2010
Last Update Posted: February 3, 2016
Last Verified: December 2015

Keywords provided by GlaxoSmithKline:
Synovial sarcoma
Adipocytic tumors
Phase II

Additional relevant MeSH terms:
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type